ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPES STAGE IV

This adverse event was reported 12 times

ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPES STAGE IV is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 RALTEGRAVIR 1 0.0002
1 BRENTUXIMAB VEDOTIN 1 0.0001
2 GOLIMUMAB 1 0.0001
3 LOPINAVIR AND RITONAVIR 1 0.0001
4 FLUDARABINE PHOSPHATE 2 0.0001
5 CYCLOPHOSPHAMIDE FOR INJECTION 3 0.0000
6 CYCLOPHOSPHAMIDE 3 0.0000
7 AZATHIOPRINE 1 0.0000
8 DOXORUBICIN 1 0.0000
9 RITUXIMAB 2 0.0000
See all drugs enriched for association with ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPES STAGE IV

ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPES STAGE IV is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD30-directed Immunoconjugate [EPC] 1 0.0001
1 Androgen [EPC] 1 0.0000
2 Protease Inhibitor [EPC] 1 0.0000
3 Cytochrome P450 3A Inhibitor [EPC] 1 0.0000
4 Alkylating Drug [EPC] 3 0.0000
5 Purine Antimetabolite [EPC] 1 0.0000
6 Calcineurin Inhibitor Immunosuppressant [EPC] 1 0.0000
7 CD20-directed Cytolytic Antibody [EPC] 2 0.0000
8 Tumor Necrosis Factor Blocker [EPC] 3 0.0000
9 Corticosteroid [EPC] 2 0.0000
See all drug classes enriched for association with ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPES STAGE IV